Myotonic Dystrophy News and Research

RSS
TSRI scientists develop new methods to design precision medicines against disease-causing RNAs

TSRI scientists develop new methods to design precision medicines against disease-causing RNAs

Tufts scientists discover reason for incidence of genetic error that causes many disorders

Tufts scientists discover reason for incidence of genetic error that causes many disorders

Researchers clarify cause of heart arrhythmia in myotonic dystrophy

Researchers clarify cause of heart arrhythmia in myotonic dystrophy

TSRI scientists develop first drug candidate that neutralizes disease-causing RNA repeats

TSRI scientists develop first drug candidate that neutralizes disease-causing RNA repeats

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

AMO Pharma raises $25 million in private equity financing

AMO Pharma raises $25 million in private equity financing

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Research could help eventual treatment of degenerative muscle, brain diseases

Research could help eventual treatment of degenerative muscle, brain diseases

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy